CL2018000711A1 - Anticuerpos que se unen específicamente a tl1a - Google Patents

Anticuerpos que se unen específicamente a tl1a

Info

Publication number
CL2018000711A1
CL2018000711A1 CL2018000711A CL2018000711A CL2018000711A1 CL 2018000711 A1 CL2018000711 A1 CL 2018000711A1 CL 2018000711 A CL2018000711 A CL 2018000711A CL 2018000711 A CL2018000711 A CL 2018000711A CL 2018000711 A1 CL2018000711 A1 CL 2018000711A1
Authority
CL
Chile
Prior art keywords
antibodies
tl1a
fibrosis
arthritis
specifically bind
Prior art date
Application number
CL2018000711A
Other languages
English (en)
Inventor
Matthew Pollard
Lynn Dorothy Poulton
Anthony G Doyle
Bridget Ann Cooksey
Vanya Pande
Adam William Clarke
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of CL2018000711A1 publication Critical patent/CL2018000711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sorting Of Articles (AREA)

Abstract

VARIANTES DE ANTICUERPOS EXPRESADAS DE MANERA RECOMBINANTE QUE TIENEN UNA AFINIDAD MEJORADA POR TL1A Y UNA POTENCIA MEJORADA CON RELACIÓN AL ANTICUERPO PARENTAL DEL CUAL DERIVARON. LOS ANTICUERPOS INHIBEN LA INTERACCIÓN ENTRE TL1A Y EL RECEPTOR DE MUERTE 3 (DR3). LOS ANTICUERPOS, O UNA COMPOSICIÓN CON LAS MISMAS, SE PUEDEN USAR PARA TRATAR UNO O MÁS ENTRE ASMA, EPOC, FIBROSIS PULMONAR, FIBROSIS QUÍSTICA, ENFERMEDAD DE INTESTINO INFLAMATORIO, UNA ENFERMEDAD GASTROINTESTINAL ASOCIADA CON FIBROSIS QUÍSTICA, ENFERMEDAD DE CROHN, COLITIS, COLITIS ULCEROSA, SÍNDROME DE INTESTINO IRRITABLE, ESOFAGITIS EOSINOFÍLICA, DERMATITIS ATÓPICA, ECZEMA, ESCLERODERMA, ARTRITIS O ARTRITIS REUMATOIDE.
CL2018000711A 2015-09-18 2018-03-16 Anticuerpos que se unen específicamente a tl1a CL2018000711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18

Publications (1)

Publication Number Publication Date
CL2018000711A1 true CL2018000711A1 (es) 2018-11-23

Family

ID=57043002

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000711A CL2018000711A1 (es) 2015-09-18 2018-03-16 Anticuerpos que se unen específicamente a tl1a

Country Status (33)

Country Link
US (4) US10138296B2 (es)
EP (2) EP3693393A1 (es)
JP (2) JP7013366B2 (es)
KR (1) KR101998535B1 (es)
CN (1) CN108137693B (es)
AR (1) AR106055A1 (es)
AU (2) AU2016323460B2 (es)
BR (1) BR122021002400A8 (es)
CA (1) CA2997015A1 (es)
CL (1) CL2018000711A1 (es)
CO (1) CO2018003736A2 (es)
CY (1) CY1123499T1 (es)
DK (1) DK3350223T3 (es)
EA (1) EA201890756A1 (es)
ES (1) ES2810751T3 (es)
HR (1) HRP20201323T1 (es)
HU (1) HUE051496T2 (es)
IL (1) IL257761B2 (es)
LT (1) LT3350223T (es)
MA (2) MA42825B1 (es)
MD (1) MD3350223T2 (es)
MX (1) MX2018003185A (es)
PE (1) PE20181080A1 (es)
PH (1) PH12018500580B1 (es)
PL (1) PL3350223T3 (es)
PT (1) PT3350223T (es)
RS (1) RS60703B1 (es)
SI (1) SI3350223T1 (es)
SM (1) SMT202000500T1 (es)
TW (1) TWI703158B (es)
UA (1) UA125284C2 (es)
WO (1) WO2017049024A1 (es)
ZA (1) ZA201801427B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017096358A1 (en) * 2015-12-04 2017-06-08 University Of Iowa Research Foundation Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
AU2018259856B2 (en) * 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
NZ787680A (en) 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN116348481A (zh) * 2020-08-19 2023-06-27 詹森生物科技公司 使用工程化配体的材料和方法
MX2023009681A (es) * 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
KR20250044336A (ko) 2022-07-27 2025-03-31 세파론 엘엘씨 궤양성 결장염 및 크론병의 치료를 위한 항-tl1a 항체
IL318297A (en) 2022-07-27 2025-03-01 Cephalon Llc Anti-TL1A antibody formulations
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
EP4731660A2 (en) * 2023-06-21 2026-04-29 Paragon Therapeutics, Inc. Tl1a antibody compositions and methods of use
CN121358765A (zh) * 2023-06-22 2026-01-16 派拉冈医疗公司 Il-23抗体组合物以及使用方法
WO2024263945A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Il-17 antibody compositions and methods of use
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US20250109209A1 (en) 2023-10-03 2025-04-03 Absci Corporation Tl1a associated antibody compositions and methods of use
CN120058933B (zh) * 2023-11-30 2026-02-10 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
CN120590530A (zh) * 2024-03-05 2025-09-05 帆礼生物技术(武汉)有限公司 靶向tl1a的抗体及其应用
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2026072993A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
WO2026072983A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of atopic dermatitis with an anti-tl1a antibody
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US20090269345A1 (en) 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
EP2519260A2 (en) 2009-12-31 2012-11-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014106602A1 (en) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
WO2014186665A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
ES2894963T3 (es) 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
MX2016002879A (es) 2013-09-06 2016-08-17 Cedars Sinai Medical Center Sistemas, dispositivos y metodos para la terapia anti-tl1a.
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
EP3283499B1 (en) 2015-04-15 2022-07-06 Biosearch Technologies, Inc. Dual quencher probes
JP2018522533A (ja) 2015-05-15 2018-08-16 シーダーズ—シナイ メディカル センター 炎症性腸疾患を処置するためのモデル、方法および組成物
EP3730188B1 (en) 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN109219620B (zh) 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
PL3774897T3 (pl) 2018-04-30 2024-01-29 Cedars-Sinai Medical Center Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
WO2020113116A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
CA3180632A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
WO2021247548A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Treatments for a sub-population of inflammatory bowel disease patients
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022119842A1 (en) 2020-12-01 2022-06-09 Cedars-Sinai Medical Center Methods and systems of stratifying inflammatory disease patients
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith
MX2023009681A (es) 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
TW202246322A (zh) 2021-02-18 2022-12-01 美商普羅米修斯生物科學股份有限公司 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
EP4330434A1 (en) 2021-04-28 2024-03-06 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
WO2023102051A1 (en) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
US20260000713A1 (en) 2021-12-01 2026-01-01 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
EP4460518A2 (en) 2022-01-07 2024-11-13 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Also Published As

Publication number Publication date
PE20181080A1 (es) 2018-07-05
US20170081400A1 (en) 2017-03-23
AU2016323460A1 (en) 2018-03-29
KR101998535B1 (ko) 2019-07-09
JP7341259B2 (ja) 2023-09-08
CN108137693B (zh) 2021-11-26
MA52643A (fr) 2021-03-24
MA42825B1 (fr) 2020-09-30
CY1123499T1 (el) 2022-03-24
CA2997015A1 (en) 2017-03-23
US11220549B2 (en) 2022-01-11
HK1256300A1 (zh) 2019-09-20
US20190106486A1 (en) 2019-04-11
LT3350223T (lt) 2020-10-26
IL257761B (en) 2022-11-01
BR122021002400A2 (es) 2018-10-09
HK1251002A1 (en) 2019-01-18
BR122021002400A8 (pt) 2023-01-24
MX2018003185A (es) 2018-08-01
TWI703158B (zh) 2020-09-01
PH12018500580B1 (en) 2023-01-11
TW201722990A (zh) 2017-07-01
EP3350223A1 (en) 2018-07-25
PH12018500580A1 (en) 2018-10-15
AU2016323460B2 (en) 2023-06-15
US20250179202A1 (en) 2025-06-05
WO2017049024A1 (en) 2017-03-23
IL257761A (en) 2018-04-30
HUE051496T2 (hu) 2021-03-01
IL257761B2 (en) 2023-03-01
CN108137693A (zh) 2018-06-08
ZA201801427B (en) 2019-06-26
JP2018528773A (ja) 2018-10-04
JP7013366B2 (ja) 2022-02-15
US20220185902A1 (en) 2022-06-16
JP2022051771A (ja) 2022-04-01
DK3350223T3 (da) 2020-08-24
SI3350223T1 (sl) 2020-10-30
EP3693393A1 (en) 2020-08-12
CO2018003736A2 (es) 2018-07-10
EA201890756A1 (ru) 2018-08-31
US10138296B2 (en) 2018-11-27
US12162946B2 (en) 2024-12-10
NZ740731A (en) 2024-07-26
AU2023203440A1 (en) 2023-06-29
BR112018005407A2 (en) 2018-10-09
HRP20201323T1 (hr) 2020-11-27
MD3350223T2 (ro) 2020-09-30
RS60703B1 (sr) 2020-09-30
SMT202000500T1 (it) 2020-11-10
EP3350223B1 (en) 2020-06-17
UA125284C2 (uk) 2022-02-16
AR106055A1 (es) 2017-12-06
PL3350223T3 (pl) 2021-03-08
BR112018005407A8 (pt) 2023-01-24
KR20180048712A (ko) 2018-05-10
ES2810751T3 (es) 2021-03-09
AU2023203440B2 (en) 2026-04-16
PT3350223T (pt) 2020-08-05

Similar Documents

Publication Publication Date Title
CL2018000711A1 (es) Anticuerpos que se unen específicamente a tl1a
ZA201803366B (en) Antibody molecules to april and uses thereof
CL2016001706A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
HUE050790T2 (hu) Rekombináns probiotikus baktérium
BR112017000505A2 (pt) mananases de paenibacillus e bacillus spp.
AR101878A1 (es) Composición blanqueadora
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
EA201790441A1 (ru) Антитела к il-25 и их применения
MX378344B (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
AR105470A1 (es) Métodos para inducir una respuesta inmune
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
Kharitonov Predictor based stabilization of neutral type systems with input delay
IL260017A (en) Lyophilized composition for preserving microbiota in its ecosystem
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
CL2016001081A1 (es) Anticuerpo anti el ligando 17 de quimioquina (ccl17) humana; composición farmacéutica que lo comprende; polinucleótido que lo codifica; vector; célula huésped; método de producción; y uso para tratar enfermedad inflamatoria, tal como asma, colitis ulcerativa, dermatitis atópica o fibrosis pulmonar idiopática
IN2014MU01248A (es)
Cohen Pairs of primitive elements in fields of even order
PH12017500426A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
FR3037077B1 (fr) Souches mutantes du genre clostridium beijerinckii
EP3501554A4 (en) COMPOSITION CONTAINING A BUFFER